Global CDMO Asymchem has made a strong impact at CPHI Milan 2024, where the company focused on advanced manufacturing technologies, as well as a growing global supply chain.
At the heart of Asymchem’s 25-year success in the CDMO space lies a commitment to technology-driven strategies. With a global workforce of over 9,000 employees, more than 45% are dedicated to research, development and analysis.
This dedication is supported by annual R&D investments that consistently range from 7–9% of the company’s revenue, allowing Asymchem to build a robust technological moat.
Currently, Asymchem holds 452 patents — with more than 300 of these being related to advanced manufacturing technologies such as continuous reactions and synthetic biology.
The company’s proprietary technology which allows the continuous immobilisation of enzymes — which combines the benefits of both continuous and batch reactions — has delivered capacity increases ranging from 20 to 1,000x.
This technology has successfully been implemented in multiple large-scale production projects.
In addition to its internal advancements, Asymchem has extended its expertise in advanced manufacturing technologies and equipment to clients, offering a comprehensive, one-stop service package that includes process development, equipment manufacturing, and other continuous reaction technical support.
Global capacity expansion
Asymchem is currently advancing its global capacity expansion. The company’s first European R&D and manufacturing facility, operational since August, has undergone significant upgrades to offer comprehensive small-molecule drug R&D services.
The facility is fully equipped to conduct high-throughput experiments, crystallisation engineering, analytical method development, cGMP quality control, process technology transfer support, chemical process development and regulatory submission support.
Additionally, as a cGxP-compliant, multiproduct pilot-scale API manufacturing site, the facility has a technical team with proven expertise in hydrogenation and low-temperature chemical production.
Plans are already in motion to integrate advanced manufacturing technologies such as synthetic biology and continuous flow reactions. Asymchem is also expanding into emerging fields, including peptide and oligonucleotide synthesis, which will further bolster its global drug R&D and manufacturing capabilities across more sectors.
